Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease

Robert Lustig, Tom Mikkelsen, Glenn Lesser, Stuart A Grossman, Xiaobu Ye, Serena Desideri, Joy Fisher, John Wright

Research output: Contribution to journalArticle

Abstract

Glioblastoma multiforme (GBM) is a lethal primary malignant brain tumor in adults. R115777 (tipifarnib) is an oral agent with antiproliferative effects, being a potent and selective inhibitor of farnesyltransferase. This multicenter, open-label phase II study was designed to evaluate the efficacy and safety of R115777 given after surgery and prior to radiation in patients with newly diagnosed and residual enhancing GBM. Following surgery, an MRI confirmed the presence of residual enhancing tumor. Patients on enzyme-inducing antisei- zure drugs (EIASDs) received 600 mg twice per day, and those not on EIASDs received 300 mg twice per day. One to three monthly cycles of R115777 were administered, and radiation was initiated with progression or after three cycles. A cycle consisted of 3 weeks of continuous R115777 followed by a 1-week rest. MRI was done monthly. The primary end point was overall survival; secondary end points were tumor response rate and toxicity. A total of 28 confirmed GBM patients entered the study; 15 patients (54%) were on EIASDs. The overall median time of survival was 7.7 months. There were no tumor responses. Eight patients (29%) had stable disease as the best response. The study was stopped early due to progression of the disease in 12 patients (48%). A total of 24 patients (85%) were off study before the planned treatment schedule for radiation therapy. R115777 administered prior to radiation therapy in patients with newly diagnosed GBM and residual enhancing disease did not result in any measurable responses or improvement in survival. R115777 administered prior to radiation therapy is not recommended for patients with newly diagnosed GBM.

Original languageEnglish (US)
Pages (from-to)1004-1009
Number of pages6
JournalNeuro-Oncology
Volume10
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

tipifarnib
Glioblastoma
Radiotherapy
Survival
Enzymes
Pharmaceutical Preparations
Radiation
Farnesyltranstransferase
Residual Neoplasm
Brain Neoplasms
Disease Progression
Neoplasms
Appointments and Schedules

Keywords

  • Glioblastoma
  • Radiation
  • Tipifarnib
  • Zar-nestra

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. / Lustig, Robert; Mikkelsen, Tom; Lesser, Glenn; Grossman, Stuart A; Ye, Xiaobu; Desideri, Serena; Fisher, Joy; Wright, John.

In: Neuro-Oncology, Vol. 10, No. 6, 12.2008, p. 1004-1009.

Research output: Contribution to journalArticle

Lustig, Robert ; Mikkelsen, Tom ; Lesser, Glenn ; Grossman, Stuart A ; Ye, Xiaobu ; Desideri, Serena ; Fisher, Joy ; Wright, John. / Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. In: Neuro-Oncology. 2008 ; Vol. 10, No. 6. pp. 1004-1009.
@article{f72ba8610d244de6a512970161e56398,
title = "Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease",
abstract = "Glioblastoma multiforme (GBM) is a lethal primary malignant brain tumor in adults. R115777 (tipifarnib) is an oral agent with antiproliferative effects, being a potent and selective inhibitor of farnesyltransferase. This multicenter, open-label phase II study was designed to evaluate the efficacy and safety of R115777 given after surgery and prior to radiation in patients with newly diagnosed and residual enhancing GBM. Following surgery, an MRI confirmed the presence of residual enhancing tumor. Patients on enzyme-inducing antisei- zure drugs (EIASDs) received 600 mg twice per day, and those not on EIASDs received 300 mg twice per day. One to three monthly cycles of R115777 were administered, and radiation was initiated with progression or after three cycles. A cycle consisted of 3 weeks of continuous R115777 followed by a 1-week rest. MRI was done monthly. The primary end point was overall survival; secondary end points were tumor response rate and toxicity. A total of 28 confirmed GBM patients entered the study; 15 patients (54{\%}) were on EIASDs. The overall median time of survival was 7.7 months. There were no tumor responses. Eight patients (29{\%}) had stable disease as the best response. The study was stopped early due to progression of the disease in 12 patients (48{\%}). A total of 24 patients (85{\%}) were off study before the planned treatment schedule for radiation therapy. R115777 administered prior to radiation therapy in patients with newly diagnosed GBM and residual enhancing disease did not result in any measurable responses or improvement in survival. R115777 administered prior to radiation therapy is not recommended for patients with newly diagnosed GBM.",
keywords = "Glioblastoma, Radiation, Tipifarnib, Zar-nestra",
author = "Robert Lustig and Tom Mikkelsen and Glenn Lesser and Grossman, {Stuart A} and Xiaobu Ye and Serena Desideri and Joy Fisher and John Wright",
year = "2008",
month = "12",
doi = "10.1215/15228517-2008-070",
language = "English (US)",
volume = "10",
pages = "1004--1009",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease

AU - Lustig, Robert

AU - Mikkelsen, Tom

AU - Lesser, Glenn

AU - Grossman, Stuart A

AU - Ye, Xiaobu

AU - Desideri, Serena

AU - Fisher, Joy

AU - Wright, John

PY - 2008/12

Y1 - 2008/12

N2 - Glioblastoma multiforme (GBM) is a lethal primary malignant brain tumor in adults. R115777 (tipifarnib) is an oral agent with antiproliferative effects, being a potent and selective inhibitor of farnesyltransferase. This multicenter, open-label phase II study was designed to evaluate the efficacy and safety of R115777 given after surgery and prior to radiation in patients with newly diagnosed and residual enhancing GBM. Following surgery, an MRI confirmed the presence of residual enhancing tumor. Patients on enzyme-inducing antisei- zure drugs (EIASDs) received 600 mg twice per day, and those not on EIASDs received 300 mg twice per day. One to three monthly cycles of R115777 were administered, and radiation was initiated with progression or after three cycles. A cycle consisted of 3 weeks of continuous R115777 followed by a 1-week rest. MRI was done monthly. The primary end point was overall survival; secondary end points were tumor response rate and toxicity. A total of 28 confirmed GBM patients entered the study; 15 patients (54%) were on EIASDs. The overall median time of survival was 7.7 months. There were no tumor responses. Eight patients (29%) had stable disease as the best response. The study was stopped early due to progression of the disease in 12 patients (48%). A total of 24 patients (85%) were off study before the planned treatment schedule for radiation therapy. R115777 administered prior to radiation therapy in patients with newly diagnosed GBM and residual enhancing disease did not result in any measurable responses or improvement in survival. R115777 administered prior to radiation therapy is not recommended for patients with newly diagnosed GBM.

AB - Glioblastoma multiforme (GBM) is a lethal primary malignant brain tumor in adults. R115777 (tipifarnib) is an oral agent with antiproliferative effects, being a potent and selective inhibitor of farnesyltransferase. This multicenter, open-label phase II study was designed to evaluate the efficacy and safety of R115777 given after surgery and prior to radiation in patients with newly diagnosed and residual enhancing GBM. Following surgery, an MRI confirmed the presence of residual enhancing tumor. Patients on enzyme-inducing antisei- zure drugs (EIASDs) received 600 mg twice per day, and those not on EIASDs received 300 mg twice per day. One to three monthly cycles of R115777 were administered, and radiation was initiated with progression or after three cycles. A cycle consisted of 3 weeks of continuous R115777 followed by a 1-week rest. MRI was done monthly. The primary end point was overall survival; secondary end points were tumor response rate and toxicity. A total of 28 confirmed GBM patients entered the study; 15 patients (54%) were on EIASDs. The overall median time of survival was 7.7 months. There were no tumor responses. Eight patients (29%) had stable disease as the best response. The study was stopped early due to progression of the disease in 12 patients (48%). A total of 24 patients (85%) were off study before the planned treatment schedule for radiation therapy. R115777 administered prior to radiation therapy in patients with newly diagnosed GBM and residual enhancing disease did not result in any measurable responses or improvement in survival. R115777 administered prior to radiation therapy is not recommended for patients with newly diagnosed GBM.

KW - Glioblastoma

KW - Radiation

KW - Tipifarnib

KW - Zar-nestra

UR - http://www.scopus.com/inward/record.url?scp=60549100910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549100910&partnerID=8YFLogxK

U2 - 10.1215/15228517-2008-070

DO - 10.1215/15228517-2008-070

M3 - Article

VL - 10

SP - 1004

EP - 1009

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 6

ER -